<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03677102</url>
  </required_header>
  <id_info>
    <org_study_id>1515</org_study_id>
    <nct_id>NCT03677102</nct_id>
  </id_info>
  <brief_title>Fluids in Septic Shock (FISSH)</brief_title>
  <acronym>FISSH</acronym>
  <official_title>Fluids in Septic Shock (FISSH): a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Physicians' Services Incorporated Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite evidence of the physiologic benefits and possible lower mortality associated with low
      chloride solutions, normal saline remains the most wildly used fluid in the world. Given
      uncertainty about the impact of lower chloride versus higher chloride solutions on mortality,
      it is unlikely that clinical practice will change without new and direct RCT evidence.
      Editorials published in leading critical care journals have called for RCT's to address this
      important clinical question. This trial will directly compare low chloride versus normal
      chloride for resuscitation in septic shock on patient-important outcomes such as mortality
      and AKI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe infection can lead to many complications within the human body including low blood
      pressure, which is called septic shock. The main treatments for septic shock are intravenous
      antibiotics and intravenous fluid.

      There are many different intravenous fluids available for doctors to use. Each one of these
      fluids has potential advantages as well as potential disadvantages. Doctors will often look
      at many things when deciding which fluid to give including the results of bloodwork and the
      clinical characteristics of the patients themselves. There is limited direction from research
      studies that using one fluid type is better than another. Some preliminary research in the
      field has suggested that one specific electrolyte, call chloride, may be harmful when given
      to patients in high concentrations. Animal research has shown that the administration of high
      chloride fluids may be harmful to the lungs, kidneys, gastrointestinal and muscle cells. Some
      intravenous fluids have higher concentrations of chloride than others.

      The investigators plan to study the impact of giving patients with severe infection
      intravenous fluids with either a high chloride concentration (normal saline or high chloride
      albumin) or a low chloride concentration (Ringers Lactate or low chloride albumin). This
      trial will build on the earlier pilot, phase 1 study and will look at patient-important
      outcomes such as rate of death, kidney failure and length of stay in the ICU. This larger
      study has the potential to guide the care of critically ill patients with infection
      worldwide.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage 2 or worse acute kidney injury (AKI)</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Development of stage 2 or worse acute kidney injury (AKI) according to KIDGO guidelines based strictly on serum creatinine criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hospital/ICU mortality</measure>
    <time_frame>up to 30 days</time_frame>
    <description>hospital/ICU mortality up to 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital/ICU length of stay</measure>
    <time_frame>up to 30 days</time_frame>
    <description>length of hospital/ICU stay up to 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ventilator free days</measure>
    <time_frame>censored at 30 days</time_frame>
    <description>number of ventilator free days, censored at 30 day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of days requiring vasoactive agents</measure>
    <time_frame>duration of time requiring intravenous vasopressors (censored at 30 days)</time_frame>
    <description>duration of time requiring vaso-active agents censored at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a serum potassium over 5mEq/L or under 3.5mEq/L</measure>
    <time_frame>up to 30 days</time_frame>
    <description>at any time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a serum sodium over 145mEq/L or under 130mEq/L</measure>
    <time_frame>up to 30 days</time_frame>
    <description>at any time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Sepsis, Septic Shock</condition>
  <arm_group>
    <arm_group_label>higher chloride solutions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>higher chloride crystalloid (Normal saline - chloride concentration 154 mmol/L)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lower chloride solutions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lower chloride crystalloid (Ringer's lactate - chloride concentration 110 mmol/L)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>higher chloride crystalloid</intervention_name>
    <description>Normal saline (chloride concentration 154 mmol/L)</description>
    <arm_group_label>higher chloride solutions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>lower chloride crystalloid</intervention_name>
    <description>Ringer's Lactate (chloride concentration 110 mmol/L)</description>
    <arm_group_label>lower chloride solutions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients 16 years or greater who meet all of the following:

          -  require fluid resuscitation for refractory hypotension (systolic blood pressure &lt;90
             mmHg or mean arterial blood pressure&lt;65 mmHg after 1 Litre bolus over 1 hour or less
             or organ hypo-perfusion (serum lactate &gt;4 mmol/L)

          -  have a clinical suspicion of infection

          -  are within 6 hours of hospital admission or critical care response team consultation

          -  are anticipated to require ICU admission

        Exclusion Criteria:

          -  intracranial bleed or intracranial hypertension during the index hospital admission

          -  10% of body surface area acute burn injury

          -  bleeding/hemorrhage as likely cause of hypotension

          -  a lack of commitment to life support

          -  have previously enrolled in FISSH, or a confounding trial (e.g. a trial examining the
             effect of other intravenous fluids in septic shock patients)

          -  been transferred from another hospital or facility &gt;6 hours since presentation to
             first hospital

          -  pre-established ESRD or are receiving hemodialysis (intermittent or continuous) at
             time of enrolment, or

          -  been admitted to ICU directly from the operating room or post anaesthetic care unit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bram Rochwerg, MSc,MD,FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bram Rochwerg, MSc,MD,FRCPC</last_name>
    <phone>905-521-2100</phone>
    <phone_ext>42111</phone_ext>
    <email>rochwerg@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peggy Austin</last_name>
    <phone>905-525-9140</phone>
    <phone_ext>22154</phone_ext>
    <email>austinp@hhsc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brantford General Hospital</name>
      <address>
        <city>Brantford</city>
        <state>Ontario</state>
        <zip>N3R 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Reeve, MD,FRCPC</last_name>
      <phone>519-751-5508</phone>
      <email>acescholes@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>William Dechert</last_name>
      <phone>519-752-7871</phone>
      <phone_ext>4531</phone_ext>
      <email>wdechert@stjosham.on.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Cook, MD,FRCPC,MSc</last_name>
      <phone>905-525-9140</phone>
      <phone_ext>22900</phone_ext>
      <email>debcook@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>France Clarke, RRT</last_name>
      <phone>905-522-1155</phone>
      <phone_ext>33633</phone_ext>
      <email>clarkef@mcmaster.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Juravinski Hospital-Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bram Rochwerg, MSc,MD,FRCPC</last_name>
      <phone>905 515 2121</phone>
      <email>bram.rochwerg@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Tina Millen, RRT</last_name>
      <phone>905-719-6133</phone>
      <email>millent@mcmaster.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Bram Rochwerg, MSc,MD,FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Meade, MD,FRCPC,MSc</last_name>
      <phone>905-525-9140</phone>
      <phone_ext>22900</phone_ext>
      <email>meadema@HHSC.CA</email>
    </contact>
    <contact_backup>
      <last_name>Lori Hand, RRT</last_name>
      <email>handlori@HHSC.CA</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gordon Boyd, MD,PhD,FRCPC</last_name>
      <phone>613-549-6666</phone>
      <phone_ext>6228</phone_ext>
      <email>gordon.boyd@kingstonhsc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Tracy Boyd</last_name>
      <phone>613-549-6666</phone>
      <phone_ext>2608</phone_ext>
      <email>Tracy.Boyd@kingstonhsc.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre - Victoria Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ian Dr Ball, MD,MSc,FRCPC</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>71513</phone_ext>
      <email>Ian.Ball@lhsc.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Eileen Campbell</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>55664</phone_ext>
      <email>Eileen.Campbell@lhsc.on.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Niagara Health, St Catharines Site</name>
      <address>
        <city>St Catharines</city>
        <state>Ontario</state>
        <zip>L2S 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erick Duan, MD, FRCPC</last_name>
      <phone>905-869-6551</phone>
      <email>erick.duan@medportal.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen E Burns, MD,FRCPC</last_name>
      <email>BurnsK@smh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Marlene Santos</last_name>
      <email>Santosmar@smh.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SANGEETA MEHTA, MD,FRCPC</last_name>
      <phone>416-586-4800</phone>
      <phone_ext>4604</phone_ext>
      <email>geeta.mehta@SinaiHealthSystem.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sumesh Shah, CCRP</last_name>
      <phone>416-586-4800</phone>
      <phone_ext>8445</phone_ext>
      <email>Sumesh.Shah@SinaiHealthSystem.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT03677102/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

